SCHEDULE 13D

                    Under the Securities Exchange Act of 1934

                            ZIOPHARM, Oncology, Inc.
                            ------------------------
                                (Name of Issuer)

                           Common Stock, no par value
                         (Title of Class of Securities)

                                   98973P 10 1
                                 (CUSIP Number)



                                 JONATHAN LEWIS
                                 --------------
                             CHIEF EXECUTIVE OFFICER
                     1180 Avenue of the Americas, Suite 1920
                            New York, New York 10036


(Name,  Address and Telephone Number of Person Authorized to Receive Notices and
 Communications)

                               September 20, 2005
             (Date of Event which Requires Filing of this Statement)


If the filing person has previously  filed a statement on Schedule 13G to report
the  acquisition  which is the subject of this  Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box .

                            CUSIP Number 98973P 10 1
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
(1)  Name of Reporting Persons: Robert Herskowitz 
     S.S. or I.R.S.  Identification Nos. of above persons:
--------------------------------------------------------------------------------
(2)  Check the Appropriate Box if a Member of a Group (See Instructions)
     (a)
     (b)
--------------------------------------------------------------------------------
(3)  SEC Use Only
--------------------------------------------------------------------------------
(4) Source of Funds (See Instructions) PF
--------------------------------------------------------------------------------
(5)  Check if Disclosure of Legal Proceedings is required Pursuant to Items 2(d)
     or 2(e)
--------------------------------------------------------------------------------




(6)  Citizenship or Place of Organization:  United States

--------------------------------------------------------------------------------
Number of Shares           (7)  Sole Voting Power: 1.26%1
Beneficially Owned
By Each Reporting          (8)  Shared Voting Power: 0.15%2
Person With
                           (9) Sole Dispositive Power: 1.26%

                           (10) Shared Dispositive Power: 0.15%
--------------------------------------------------------------------------------
(11)   Aggregate Amount Beneficially Owned by Each Reporting Person: 100,973
--------------------------------------------------------------------------------
(12)    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see
        Instructions).
--------------------------------------------------------------------------------
(13) Percent of Class Represented by Amount in Row (11): 1.41%

--------------------------------------------------------------------------------
(14) Type of Reporting Person (See Instructions): IN

--------------------------------------------------------------------------------
(3)  Name of Reporting Persons:  Johanna Guttmann 
     S.S. or I.R.S.  Identification Nos. of above persons:
--------------------------------------------------------------------------------
(4)  Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)
    (b)
--------------------------------------------------------------------------------
(3)  SEC Use Only
--------------------------------------------------------------------------------
(4) Source of Funds (See Instructions) PF
--------------------------------------------------------------------------------
(5)  Check if Disclosure of Legal Proceedings is required Pursuant to Items 2(d)
     or 2(e)

--------------------------------------------------------------------------------
(6)  Citizenship or Place of Organization:  United States

--------------------------------------------------------------------------------
Number of Shares           (7)  Sole Voting Power: 0
Beneficially Owned
By Each Reporting          (8)  Shared Voting Power: 0.15%2
Person With
                           (9) Sole Dispositive Power: 0%

                          (10) Shared Dispositive Power: 0.15%
--------------------------------------------------------------------------------
(11)   Aggregate Amount Beneficially Owned by Each Reporting Person: 10,750
--------------------------------------------------------------------------------
(12)    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see
        Instructions).
--------------------------------------------------------------------------------
(13) Percent of Class Represented by Amount in Row (11): 0.15%

--------------------------------------------------------------------------------
(14) Type of Reporting Person (See Instructions): IN

------------------------
1 Includes 90,223 shares Mr.  Herskowitz  individually  owns,  including  83,348
shares underlying an option for Chase Financing Inc., to which Mr. Herskowitz is
President.  The option is currently exercisable and the aggregate exercise price
for it is $1,000.  Since Mr.  Herskowitz  is the  President of Chase,  he may be
deemed to be the  beneficial  owner of all such shares of common  stock owned by
Chase.
2 Includes 10,750 shares Mr. Herskowitz owns with Johanna Guttmann as Tenants by
the Entirety.  Prior to the merger between Ziopharm Oncology,  Inc. and EasyWeb,
Inc., which took place on September 15, 2005, these shares  represented 5.66% of
EasyWeb,  Inc. Although neither Mr. Herskowitz nor Ms. Guttman,  individually or
together now own 5% or more of Ziopharm  Oncology,  Inc.,  their 5.66% ownership
was  mistakenly not previously  reported.  Therefore,  this is a late filing but
reports information as of the filing date.






ITEM 1.  SECURITY AND ISSUER.

This statement  relates to the common stock, no par value per share (the "Common
Stock"), of ZIOPHARM, Oncology, Inc. a Delaware corporation (the "Company").

The  Company's  principal  offices are located at business at 1180 Avenue of the
Americas, Suite 1920, New York, New York 10036.

Item 2.  Identity and Background.

    (a) This statement is filed by Robert Herskowitz and Johanna  Guttmann,  who
        are both natural persons.
    (b) Robert  Herskowitz's  business  address is P.O.  Box 403303 Miami Beach,
        Florida 33140.  Johanna Guttmann's  business address is P.O. Box 755 New
        York, New York 10024.
    (c) Robbert  Herskowitz's  principal  occupation  is as Business  Executive.
        Johanna Guttmann's principal occupation is as Business Executive.
    (d) During  the past  five  years,  neither  filer has been  convicted  in a
        criminal   proceeding   (excluding   traffic   violations   or   similar
        misdemeanors).
    (e) During the past five  years,  neither  filer has been a party to a civil
        proceeding   of  a  judicial  or   administrative   body  of   competent
        jurisdiction  and as a result of such  proceeding  was the  subject to a
        judgment,  decree or final  order  enjoining  future  violations  of, or
        prohibiting  or  mandating  activities  subject  to,  federal  and state
        securities laws of findings any violation with respect to such laws.
    (f) Both filers are citizens of the United States.

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.


ITEM 4. PURPOSE OF TRANSACTION


ITEM 5.  INTEREST IN SECURITIES OF THE ISSUER

    (a) Robert  Herskowitz  controls  90,223 of the 7,157,865 of the outstanding
        shares of the Company.  Robert  Herskowitz and Johanna  Guttmann control
        10,750 of the 7,157,865 of the outstanding shares of the Company.
    (b) Robert  Herskowitz has sole power to vote or to direct the vote and sole
        power to dispose  or direct the  disposition  of 90,223  shares.  Robert
        Herskowitz  and Johanna  Guttmann have shared power to vote or to direct
        the vote and shared  power to dispose  or direct the  disposition  of to
        10,750 shares.
    (b) No transactions in the class of securities reported were effected during
        the past sixty days or since the most recent filing of a Schedule 13(D).
    (c) No other  person  is known to  Robert  Herskowitz  to have the  right to
        receive  or the  power to direct  the  receipt  of  dividends  from,  or
        proceeds from the sale of, the 90,223  shares  listed above.  No person,
        other  than the  filers  are known to have the right to  receive  or the
        power to direct the receipt of dividends from, or proceeds from the sale
        of, the 10,750 shares listed above.




    (d) n/a

ITEM 6.  CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT
         TO SECURITIES OF THE ISSUER.



ITEM 7.  MATERIAL TO BE FILED AS EXHIBITS.


SIGNATURE

After  reasonable  inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.

Date:  September 26, 2005

Signature:   /s/ Robert Herskowitz
             ---------------------

Name/Title: Robert Herskowitz

Signature:  /s/ Johanna Guttmann
            --------------------

Name/Title: Johanna Guttmann